Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

被引：22

作者：

de Langen, Adrianus J. ^{[1
]}

Smit, Egbert F. ^{[1
,2
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Pulm Dis, De Boelelaan 1117, NL-1007 MB Amsterdam, Netherlands

[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2017年 / 9卷 / 01期

关键词：

BRAF; NSCLC; TKI; BLADDER-CARCINOMA ONCOGENE; RAF INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; B-RAF; CLINICOPATHOLOGICAL FEATURES; CONFER RESISTANCE; IMPROVED SURVIVAL; MEK INHIBITION; MAPK PATHWAY;

D O I：

10.1177/1758834016670555

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung adenocarcinoma is known for its high rate of somatic mutations and genomic rearrangements. The identification of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements that sensitize tumors to specific drugs has changed the therapeutic approach and prognosis in these molecularly-defined subgroups. Several other key genetic alterations have been identified, of which BRAF mutations are found in 4% of non-small cell lung cancer (NSCLC) cases. Targeted drugs against BRAF and downstream MEK were recently approved for the treatment of BRAF-positive melanoma and have entered clinical evaluation in NSCLC. In this review we discuss the latest evidence on the treatment of BRAF-mutated NSCLC, including tumor biology, targeted treatment with BRAF and MEK inhibitors, therapeutic resistance and strategies to overcome resistance.

引用

页码：46 / 58

页数：13

共 99 条

[1]

Ali S., 2015, EUR J CANC S3, V51

[2] BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition [J].

Andrews, Miles C. ;

Behren, Andreas ;

Chionh, Fiona ;

Mariadason, John ;

Vella, Laura J. ;

Do, Hongdo ;

Dobrovic, Alexander ;

Tebbutt, Niall ;

Cebon, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) :E448-E451

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Vemurafenib and Radiosensitization [J].

Boussemart, Lise ;

Boivin, Catherine ;

Claveau, Joel ;

Tao, Yun Gan ;

Tomasic, Gorana ;

Routier, Emilie ;

Mateus, Christine ;

Deutsch, Eric ;

Robert, Caroline .

JAMA DERMATOLOGY, 2013, 149 (07) :855-857

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6]

Brose MS, 2002, CANCER RES, V62, P6997

[7] BRAF-mutations in non-small cell lung cancer [J].

Brustugun, Odd Terje ;

Khattak, Asma Malik ;

Tromborg, Anette Kjoshagen ;

Beigi, Marzieh ;

Beiske, Klaus ;

Lund-Iversen, Marius ;

Helland, Aslaug .

LUNG CANCER, 2014, 84 (01) :36-38

[8] Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment [J].

Callahan, Margaret K. ;

Rampal, Raajit ;

Harding, James J. ;

Klimek, Virginia M. ;

Chung, Young Rock ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Solit, David B. ;

Rosen, Neal ;

Abdel-Wahab, Omar ;

Levine, Ross L. ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (24) :2316-2321

[9] Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma [J].

Capaldo, Brian J. ;

Roller, Devin ;

Axelrod, Mark J. ;

Koeppel, Alex F. ;

Petricoin, Emanuel F. ;

Slingluff, Craig L., Jr. ;

Weber, Michael J. ;

Mackey, Aaron J. ;

Gioeli, Daniel ;

Bekiranov, Stefan .

PLOS ONE, 2015, 10 (09)

[10] Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer [J].

Cardarella, Stephanie ;

Ogino, Atsuko ;

Nishino, Mizuki ;

Butaney, Mohit ;

Shen, Jeanne ;

Lydon, Christine ;

Yeap, Beow Y. ;

Sholl, Lynette M. ;

Johnson, Bruce E. ;

Jaenne, Pasi A. .

CLINICAL CANCER RESEARCH, 2013, 19 (16) :4532-4540

← 1 2 3 4 5 6 7 8 9 10 →